CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL

BACKGROUND: CC-115 is an oral, CNS-penetrant, selective inhibitor of mammalian target of rapamycin kinase (mTOR) and deoxyribonucleic acid-dependent protein kinase (DNA-PK). Both targets are important in glioblastoma; PI3K/Akt/mTOR signaling is hyperactive in most glioblastomas, and DNA-PK is integr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Rahman, Rifaquat, Trippa, Lorenzo, Fell, Geoffrey, Lee, Eudocia, Arrillaga-Romany, Isabel, Touat, Mehdi, McCluskey, Christine, Brunno, Jennifer, Gaffey, Sarah, Drappatz, Jan, Lassman, Andrew, Galanis, Evanthia, Ahluwalia, Manmeet, Colman, Howard, Nabors, Louis, Hepel, Jaroslaw, Elinzano, Heinrich, Schiff, David, Chukwueke, Ugonma, Beroukhim, Rameen, Nayak, Lakshmi, Mcfaline-Figueroa, Jose, Batchelor, Tracy, Rinne, Mikael, Kaley, Thomas, Lu-Emerson, Christine, Bi, Wenya Linda, Arnaout, Omar, Haas-Kogan, Daphne, Tanguturi, Shyam, Cagney, Daniel, Aizer, Ayal A, Welch, Mary, Doherty, Lisa, Lavallee, Maria, Fisher-Longden, Brittany, Dowling, Shanna, Geduldig, Jack, Watkinson, Fiona, Santagata, Sandro, Meredith, David, Chiocca, E Antonio, Reardon, David, Ligon, Keith, Alexander, Brian, Wen, Patrick
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Trials: Non-Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650886/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.178
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados